The pivot where membrane building meets signaling: diacylglycerol (DAG) is a glycerol carrying two fatty acyl chains — spawned when phospholipase C splits PIP2, it activates protein kinase C within seconds, then doubles as the obligate precursor for triacylglycerol and phospholipid assembly.
Lipid Class
Glycerolipid (glyceride with two esterified acyl chains)
Core Composition
Glycerol plus two fatty acid chains; 1,2- and 1,3-isomers
The signaling pool is made on demand: phospholipase C hydrolyzes PIP2 into inositol trisphosphate plus DAG, the two-arm inositol phosphate response.
Lipolysis also passes through: adipose triglyceride lipase converts triacylglycerol to DAG inside adipocytes.
Termination by phosphorylation: diacylglycerol kinase converts DAG back to phosphatidic acid.
Physiological Role
Signal: DAG is a physiological activator of protein kinase C, and its production in the membrane pulls PKC from cytosol to the plasma membrane.
Build: addition of a third fatty acid converts DAG into triacylglycerol, while CDP-choline condenses with DAG to form phosphatidylcholine — the Kennedy pathway's final step.
With monoacylglycerol and free fatty acids it forms the neutral lipid intermediates connecting storage and signaling pools.
PKC-theta activation by DAG may cause insulin resistance in muscle by decreasing IRS1-associated PI3K activity — a direct tie into the PI3K-Akt pathway and insulin action.
Clinical Relevance
DAG accumulation activating PKC is a candidate mechanism behind muscle insulin resistance.
1,3-DAG-enriched oil has been investigated extensively as a fat substitute for its ability to suppress body fat accumulation; such oils reached roughly two hundred million dollars in annual sales in Japan.